We are thrilled to announce that Diana Macdonell, former Head, Secretariat, Pharmaceutical Benefits Advisory Committee, Australia is confirmed to attend World Orphan Drug Congress USA 2016!
The rare disease industry’s only global gathering returns for its 6th year, bigger and better than ever. I think it’s safe to say that for the very first time, the World Orphan Drug Congress USA is bringing together payers from US, Europe and Australia together. They’ll be sharing best practice in orphan drug reimbursements and deliberations. We also asked them to talk about their challenges in this area.
Diana Macdonell, former Head, Secretariat, Pharmaceutical Benefits Advisory Committee, Australia will be giving you insight into “Orphan drugs – the Australian approach to reimbursement.”
Join her on April 20th to hear about:
- A brief outline of the Australian Pharmaceutical Benefits Scheme (PBS) and the operation of the Pharmaceutical Benefits Advisory Committee (PBAC)
- Particular requirements for data for listing orphan drugs on the PBS
- Suggestions for overcoming data deficiencies for orphan drugs, including types of statistical analysis to account for issues such as crossover
- Other approaches to funding of orphan drugs – existing and potential ideas
*Please note that access to this session is limited to those who purchase a 3 day or a 2.5 day ticket.